# Tumor-normal versus tumor-only sequencing

Source: https://onco.cc/terms/tumor-normal-vs-tumor-only-sequencing/  
OnCo record `tumor-normal-vs-tumor-only-sequencing` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Comparing tumour and suitable normal DNA helps distinguish acquired changes from inherited ones.

## Summary

A matched normal is a separately collected specimen from the same person chosen to represent constitutional DNA; normal is an analytical role, not a guarantee of uncomplicated cells; it differs from a healthy reference cohort.

## Fields

- Kind: Term
- Last checked: 2026-11-10

## Notes

- A matched normal is a separately collected specimen from the same person chosen to represent constitutional DNA; normal is an analytical role, not a guarantee of uncomplicated cells; it differs from a healthy reference cohort.
- Evidence in the normal supports constitutional origin; adequate tumour and normal depth with no normal support supports somatic origin; inadequate normal depth leaves an attribution gap and absence there is uninformative.
- Tumour-only workflows infer origin from population databases, allele fractions and models; rare germline variants may be absent from databases; a hotspot or familiar gene does not prove tumour-only origin.
- In Jones et al. (2015), 815 tumour-normal pairs across 15 tumour types, germline changes in cancer-predisposing genes were found in 3% of patients with apparently sporadic cancers; tumour-only analysis could not definitively identify them and added false positives of 31% (targeted) and 65% (exome) of alterations.
- Origin does not establish function, hereditary-risk conclusions or drug benefit; paired research sequencing is not a validated hereditary test.
- Fictional teaching exercise: A tumour-only rare repair-gene variant at 48% allele fraction absent from databases cannot be labelled inherited or somatic from those facts; review copy state and attribution model.
- Retain specimen identity, suitable normal tissue, extraction consumption, reference coordinates, both support counts and fractions, attribution rules and uncertainty. Normal sampling need not require a second tumour biopsy. Mismatch, contamination, low normal coverage and rare constitutional variants can mislead; validate the intended somatic/germline workflow and confirmation policy separately.

## Sources

- Personalized genomic analyses for cancer mutation discovery and interpretation.: https://pubmed.ncbi.nlm.nih.gov/25877891/
- Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.: https://pubmed.ncbi.nlm.nih.gov/28341590/

## Connected records

- terms: [Next-generation sequencing (NGS)](https://onco.cc/terms/ngs/)

---
JSON: https://onco.cc/api/v1/entities/tumor-normal-vs-tumor-only-sequencing.json